Children's Cancer Research FUND
Families and Friends Who care

Children's Cancer Research Fund's 2008 Grant Application
PDF Format or Word Document


In the sixteen years of funding, CCRF has just awarded its 54th research grant!  Since 
Children's Cancer Research Fund is not the arm of any one hospital, it is able
 to fund research on a national level.

Children's Cancer Research Fund is not the arm of any one hospital, it is able
 to fund research on a national level.

2007

ASGHARZADEH, SHAHAB, M.D.
  Childrens Hospital Los Angeles
  Los Angeles, California
  *Genomics of Metastatic Neuroblastomas Lacking MYCN Amplification.

GREGORY, MARK A., Ph.D.
  University of Colorado Health Sciences Center
  Aurora, Colorado
  *Identifying Candidates for Targeted Therapy in Combination with FLT3 Inhibition for the Treatment of
    Acute Myeloid Leukemia.

WELLS, JAMES, M.D.
  Bringham and Women's Hospital, Inc.
  Boston, Massachusetts
  *EWS-Flil as an Immuno-Therapeutic Target for Ewing's Sarcoma.

2006

ARMSTRONG, MICHAEL B., M.D., PH.D.
  University of Michigan Comprehensive Cancer Center
  Ann Arbor, Michigan
  *Impact of N-myc on Chemoresistance in Neuroblastoma.

HELLER, KEVIN N., M.D.
  The Rockefeller University
  New York, New York
  *Epstein-Barr Virus Immunity and Lymphoma.

KEATING, AMY K., M.D.
  UCHSC at Fitzsimmons, Pediatrics
  Aurora, Colorado
  *Mer Receptor Tyrosine Kinase as a Biological Marker and Therapeutic Target for Pediatric Leukemia.

RABIN, KAREN, M.D.
  Texas Children’s Cancer Center
  Houston, Texas
  *Acute Lymphoblastic Leukemia in Down Syndrome: An Investigation of Molecular Genetics 
    and Host Toxicity.

2005

BARRY, ELLY FALZARANO, M.D.
  Dana Farber Cancer Institute
  Boston, Massachusetts
  *Pharmacogenomics of Doxorubicin-induced Cardiotoxicity.

KEATES-BALEEIRO, JENNIFER, M.D.
  Vanderbilt Children's Hospital
  Nashville, Tennessee
  *Testing Novel Therapeutics in a Mouse Model if Inv (16).

ZACHAROULIS, STERGIOS, M.D.
  Childrens Hospital Los Angeles
  Los Angeles, California
  *Preclinical Evaluation of VEGFR2/EGFR Inhibition in Combination with MetronomicTemozolomide
    in a Mouse Model of High Grade Gliomas.

2004
HAINING, W. NICHOLAS, B.M., B.CH.
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  *Targeting telomerase as a cancer antigen: a phase 1 pediatric tumor
    vaccine trial.

KARAJANNIS, MATTHIAS, A., M.D.
  Memorial Sloan-Kettering Cancer Center
  New York, New York
  *Role of pro-angiogenic factors in leukemia-stroma interactions.

ONEL, KENAN, M.D., PH.D.
  The University of Chicago
  Chicago, Illinois
  *The Identification of Novel Biomarkers and Therapeutic Targets in
    Pediatric ALL by Correlative Analysis of Genome Copy Number
    Alterations, mRNA Expression, and Clinical Characteristics.

2003
ASGHARZADEH, SHAHAB, M.D.
  Childrens Hospital Los Angeles
  Los Angeles, California
  *Gene Expression Profiles of Metastic Neuroblastomas without MYCN
    Amplification Predict Outcome.

ERDREICH-EPSTEIN, ANAT, M.D., PH.D.
  Childrens Hospital Los Angeles
  Los Angeles, California
  *The antiangiogenic effect of alphav-integrin inhibition combined with
    fenretinide in mouse models of human brain tumors.

REID, GREGOR, M.D., PH.D.
  BC Research Institute for Child and Family Health
  Vancouver, British Columbia
  *Development of immune therapy for ETV6-AML1 positive leukemia
    using a novel mouse model.

2002
APLENE, RICHARD, M.D.
  Children's Hospital of Philadelphia
  Philadelphia, Pennsylvania
  * Genetic Polymnorphisms and Anthracycline Associated
     Cardiac Toxicity.

BROWN, VALERIE I., M.D., PH.D.
  Children's Hospital of Philadelphia
  Philadelphia, Pennsylvania
  * Evaluation of mTOR Inhibitors and the Role of IL-7 Signaling in
     Lymphoid Malignancies.

GRAHAM, DOUGLAS K., M.D., PH.D.
  University of Colorado Cancer Center
  Denver, Colorado
  * Evaluation of role of proto-oncogene c-mer in acute
     lymphocytic leukemia.

PUNAM, MALIK, M.D.
  Childrens Hospital Los Angeles
  Los Angeles, California
  * In Vivo Effects of Erythropoietin Receptor Signaling in Pediatric
     Tumors.

2001
BATRA, SANDEEP, M.D.
  Childrens Hospital Los Angeles
  Los Angeles, California
  * Activity of fenretinide (4-HPR) and 4-HPR plus safingol in
     preventing disease progression against pediatric Ewing's
     Sarcoma (ES) and Primitive neuroectodermal Tumors (PNET)
     cell lines In Vitro and In Vivo.

MALIK, PUNAM, M.D.
 Childrens Hospital Los Angeles
  Los Angeles, California
  * Role of Erythropoietin and Erythropoietin Receptor in Pediatric 
     Tumors.

ROOD, BRIAN, M.D.
  Children's National Medical Center
  Washington, D.C.
  * Methylation of the O⁶-methylguanine methyltransferase
     (MGMT) gene promoter as a prognostic factor in pediatric high
     grade glioma and medulloblastoma.

WEIGEL, BRENDA, M.D.
  University of Minnesota Medical School
  Minneapolis, Minnesota
  * Combination Immunotherapy and Chemotherapy for
     Rhabdomyosarcoma.

2000
MAURER, BARRY J., M.D.,  PH.D.
  Childrens Hospital Los Angeles
  Los Angeles, California
  * Novel Retinoid Combinations with Selective Cytotoxicity for
     Malignant Cells.

WANG, LISA L., M.D.
  Baylor College of Medicine, Texas Children's Cancer Center
  Houston, Texas
  * Molecular Basis and Clinical Spectrum of Rothmund-Thomson
     Syndrome.
  
1999
SAVASAN, SUREYYA, M.D.
  Wayne State University
  Detroit, Michigan
  * In Vitro Drug-Induced Apoptosis as a Measure of Chemo-
     sensitivity in Childhood T-Cell Acute Lymphoblastic Leukemia.

VAN TORNOUT, JAN M., M.D., M.S.
  Childrens Hospital Los Angeles
  Los Angeles, California
  * Evidence for Gene - Environmental Interaction(s) in the
     Etiology of Pediatric Brain Cancer.

SWEETSER, DAVID A., M.D., PH.D.
  Fred Hutchinson Cancer Research Center
  Seattle, Washington
  * The Significance of Loss of Heterozygosity in the Patho-
     genesis and Prognosis of Pediatric de novo AML.

1998
Fu, Cecilia, M.D.
  USC School of Medicine/Childrens Hospital Los Angeles
  Los Angeles, California
  * Evaluation of Apoptotic Oncoproteins in Blast Cells from 
     Pediatric Patients with Leukemia at Diagnosis and at Relapse.

KESHELAVA, NINO, M.D.
  USC School of Medicine/Childrens Hospital
  Los Angeles, California
  * Resistance to Alkylating Agents in Neuroblastoma.

1997
MALONEY, KELLY, M.D.
   University of Colorado Health Sciences Center
   Denver, Colorado
   * Retrospective Analysis of Prognostic Import of TEL 
      Rearrangements and Hyperdiploidy on Treatment Outcomes 
      for Children with Standard Risks ALL treated with a Single 
      Delayed Intensification.

SHOHET, JASON, M.D.
   University of Texas Southwestern Medical Center
   Dallas, Texas
   * Analysis of Differentially Expressive Genes in Normal and 
      Neoplastic B-Cells.

1996
ORCHARD, PAUL, M.D.
   University of Minnesota
   Minneapolis, Minnesota
   * Expression of anti-CD 19 scFv/zeta Chimeric Gene in Human 
      NK Cells.

ERDREICH-EPSTEIN, ANAT, M.D., PH.D.
   USC School of Medicine/Childrens Hospital Los Angeles
   Los Angeles, California
   * Integrin Alpha-v Beta-3 in Angiogenic Signaling in Pediatric 
      Neural Tumors.

1995
ERDREICH-EPSTEIN, ANAT, M.D., PH.D.
   USC School of Medicine/Childrens Hospital Los Angeles
   Los Angeles, California
   * Integrin Alpha-v Beta-3 in Angiogenic Signaling in Pediatric 
      Neural Tumors.

TAUB, JEFFREY, M.D.
   Children's Hospital of Michigan
   Detroit, Michigan
   * The Molecular Basis of Cytarabine Sensity of Down
      Syndrome Children.

1994
WEST, DANIEL C., M.D.
   Dana-Farber Cancer Institute/Harvard Medical School
   Boston, Massachusetts
   * Testing the feasibility of using the PCR Technique to measure
      the presence of Ewing's Sarcoma or Peripheral Neuraoecto-
      dermal Tumors.

SCHMIDT, MARY LOU, M.D.
   Northwestern University Children's Memorial Hospital
   Chicago, Illinois
   * The Biologic Effects of Down-regulation of N-myc Oncogene 
      Expression in Human Neuroblastoma. (continued study)

1993
HAMRE, MERLIN R., M.D., M.P.H.
   Children's Memorial Institute for Education and Research
   Chicago, Illinois
   * Mechanisms of Resistance to Nucleoside Analogue Inhibitors 
      of S-Adenosyl-L-Homocysteine hydrolase in Murine and 
      Human Neuroblastoma Tumor Cell Lines: Enzymatic and 
      Genetic Determinants.

WHITLOCK, JAMES, A., M.D.
   Vanderbilt University Medical Center
   Nashville, Tennessee
   * Acquired and Constitutional Alterations of p53 in the Devel-
      opment and Progression of Childhood Central Nervous 
      System Tumors.

1992
EMANUEL, PETER D., M.D.
   University of Alabama at Birmingham
   Birmingham, Alabama
   * Mechanisms of Response and Effectiveness of 13-Cis 
      Retinoic Acid in the Treatment of Juvenile Chronic 
      Myelogenous Leukemia.

TOMLINSON, GALE E., M.D., PH.D.
   University of Texas Southwestern Medical Center
   Dallas, Texas
   * A Search for predisposition factors in Breats/Sarcoma Cancer 
      Families.

SCHMIDT, MARY LOU, M.D.
   Northwestern University Children's Memorial Hospital
   Chicago, Illinois
   * The Biologic Effects of Down-regulation of N-myc Oncogene 
      Expression in Human Neuroblastoma.

SHANNON, KEVIN, M.D.
   University of California, San Francisco
   San Francisco, California
   * Mutations of the Neurofibromatosis and Ras Genes in 
      Childhood Myeloproliferative Syndromes.

1991
MOULTON, THOMAS, M.D.
   Columbia University College of Physicians & Surgeons
   New York, New York
   * The Role of Classic Multidrug Resistance in Pediatric Solid 
      Tumors.

RAUCK, AMANDA M., M.D.
   Children's Hospital
   Columbus, Ohio
   * Urokinase and It's Receptor in Pediatric Cancers - the Tumor
      Biology of Wilms' Tumor and Neuroblastoma, Development 
      and Metastasis.

UMIEL, TEHILA, PH.D.
   Children's Hospital of Los Angeles
   Los Angeles, California
   * Isolation, Molecular Characterization and Induction of Differ-
      entiation of Mixed Lineage (Myeloid/Lymphoid) Precursors
      from Norman and Leukemic Human Bone Marrow.

SCHMIDT, MARY LOU, M.D.
   Northwestern University Children's Memorial Hospital
   Chicago, Illinois
   * Inhibition of N-myc Gene Expression with Antisense N-myc 
      RNA.

HUANG, CHIEN-SHENG, M.D.
   University of California, San Diego
   La Jolla, California
   * Use of Ch14.18 and GM-CSF Neuroblastoma.

VAN TORNOUT, JAN M.A., M.D.
   Children's Hospital of Los Angeles
   Los Angeles, California
   * The Use of Neural Networking in Pediatric Outcome of 
      Childhood Cancer.

TOMLINSON, GAIL E., M.D., PH.D.
   University of Texas Southwestern Medical Center
   Dallas, Texas
   * Constitutional p53 Mutations in Childhood Patients.

1990
SAYLORS, ROBERT L. III, M.D.
   Washington University School of Medicine
   St. Louis, Missouri
   * C-myc Activation in Medulloblastoma.

SMITH, THOMAS J., M.D.
   National Jewish Center for Immunology and Respiratory 
   Medicine
   Denver, Colorado
   * Vbeta Specificity of T-cell Leukemia and other T-cell 
      Lymphoproliferative Disorders.

VILLABLANCA, JUDITH, M.D.
   Children's Hospital of Los Angles
   Los Angeles, California
   * Significance of Cellular Proliferation in Neuroblastoma.

1989
WINICK, NAOMI J., M.D.
   University of Texas Southwestern Medical Center
   Dallas, Texas
   * 6-Mercaptopurine Metabolism in Children with Acute
      Lymphoblastic Leukemia.

GREFFE, BRIAN, M.D.
   The Children's Hospital
   Denver, Colorado
   * Effect of L-Asparaginase on the regulatory coagulation
      proteins and vWF as a mechanism for thrombosis in children 
      with leukemia and lymphoma. 

Children's Cancer Research Fund
11633 San Vicente Boulevard, Suite 106
Los Angeles, California  90049
Phone: 310.207.5330  Fax: 310.207.5336
E-mail: ccrfkids@hotmail.com